EP1606301A4 - APTAMERIC THERAPEUTIC AGENTS USEFUL IN OCULAR PHARMACOTHERAPY - Google Patents

APTAMERIC THERAPEUTIC AGENTS USEFUL IN OCULAR PHARMACOTHERAPY

Info

Publication number
EP1606301A4
EP1606301A4 EP04704120A EP04704120A EP1606301A4 EP 1606301 A4 EP1606301 A4 EP 1606301A4 EP 04704120 A EP04704120 A EP 04704120A EP 04704120 A EP04704120 A EP 04704120A EP 1606301 A4 EP1606301 A4 EP 1606301A4
Authority
EP
European Patent Office
Prior art keywords
aptameric
pharmacotherapy
ocular
therapeutic agents
agents useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04704120A
Other languages
German (de)
French (fr)
Other versions
EP1606301A2 (en
Inventor
David Epstein
Dilara Grate
Jeffrey Kurz
Nicholas Marsh
Thomas G Mccauley
Charles Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archemix Corp
Original Assignee
Archemix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp filed Critical Archemix Corp
Publication of EP1606301A2 publication Critical patent/EP1606301A2/en
Publication of EP1606301A4 publication Critical patent/EP1606301A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP04704120A 2003-01-21 2004-01-21 APTAMERIC THERAPEUTIC AGENTS USEFUL IN OCULAR PHARMACOTHERAPY Withdrawn EP1606301A4 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US44134703P 2003-01-21 2003-01-21
US441347P 2003-01-21
US46309503P 2003-04-15 2003-04-15
US463095P 2003-04-15
US46417903P 2003-04-21 2003-04-21
US464179P 2003-04-21
US46505503P 2003-04-23 2003-04-23
US465055P 2003-04-23
US46962803P 2003-05-08 2003-05-08
US469628P 2003-05-08
US47468003P 2003-05-29 2003-05-29
US474680P 2003-05-29
US49101903P 2003-07-29 2003-07-29
US491019P 2003-07-29
US51207103P 2003-10-17 2003-10-17
US512071P 2003-10-17
US53704504P 2004-01-16 2004-01-16
US53720104P 2004-01-16 2004-01-16
US537045P 2004-01-16
US537201P 2004-01-16
PCT/US2004/001661 WO2004064760A2 (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy

Publications (2)

Publication Number Publication Date
EP1606301A2 EP1606301A2 (en) 2005-12-21
EP1606301A4 true EP1606301A4 (en) 2006-06-14

Family

ID=32777434

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04704120A Withdrawn EP1606301A4 (en) 2003-01-21 2004-01-21 APTAMERIC THERAPEUTIC AGENTS USEFUL IN OCULAR PHARMACOTHERAPY

Country Status (5)

Country Link
EP (1) EP1606301A4 (en)
JP (1) JP2006516288A (en)
AU (1) AU2004206955A1 (en)
CA (1) CA2513004A1 (en)
WO (1) WO2004064760A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005110489A2 (en) * 2004-04-13 2005-11-24 (Osi) Eyetech, Inc. Nucleic acid aptamers conjugated to high molecular weight steric groups
EP3034089A1 (en) * 2004-11-02 2016-06-22 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2006119643A1 (en) * 2005-05-12 2006-11-16 Replicor Inc. Anti-ocular angiogenesis molecules and their uses
KR101584468B1 (en) * 2006-03-08 2016-01-13 아케믹스 엘엘씨 Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010035768A1 (en) * 2008-09-25 2010-04-01 参天製薬株式会社 Prophylactic or therapeutic agent for retinal diseases comprising polyalkylene glycol as active ingredient
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
JP6041373B2 (en) * 2010-02-01 2016-12-07 Ｎｅｃソリューションイノベータ株式会社 Aptamer molecule that binds to TNF-α
CN106074591B (en) 2010-03-24 2020-01-14 菲奥医药公司 RNA interference in ocular symptoms
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
CA2868096C (en) 2012-03-28 2019-12-31 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
AU2014286996A1 (en) * 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
US9695424B2 (en) 2013-09-09 2017-07-04 Somalogic, Inc. PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
EP3077050B1 (en) * 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2017094897A1 (en) * 2015-12-04 2017-06-08 全薬工業株式会社 Anti-il-17 aptamer having improved retention in blood
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2018148333A1 (en) * 2017-02-08 2018-08-16 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
BR112020014428A2 (en) 2018-01-19 2020-12-01 Cytokinetics, Inc. compound, pharmaceutical composition, and, methods for the treatment of heart disease in an individual, for the treatment of a disease or condition that is associated with small left ventricular cavity and cavity obliteration, hyperdynamic contraction of the left ventricle, myocardial ischemia or cardiac fibrosis, for the treatment of a disease or condition selected from muscular dystrophies and glycogen storage diseases and for inhibition of the cardiac sarcomere
JP7610985B2 (en) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド Cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020120256A1 (en) * 2018-12-11 2020-06-18 Université De Strasbourg Aptamer and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009156A1 (en) * 1999-07-29 2001-02-08 Gilead Sciences, Inc. HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
ATE406914T1 (en) * 2000-02-10 2008-09-15 Massachusetts Eye & Ear Infirm PHOTODYNAMIC THERAPY FOR THE TREATMENT OF EYE DISEASES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009156A1 (en) * 1999-07-29 2001-02-08 Gilead Sciences, Inc. HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS

Also Published As

Publication number Publication date
CA2513004A1 (en) 2004-08-05
AU2004206955A1 (en) 2004-08-05
JP2006516288A (en) 2006-06-29
EP1606301A2 (en) 2005-12-21
WO2004064760A3 (en) 2005-10-27
WO2004064760A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
EP1606301A4 (en) APTAMERIC THERAPEUTIC AGENTS USEFUL IN OCULAR PHARMACOTHERAPY
LU92915I2 (en) IVERMECTIN FOR USE IN THE TREATMENT OF ROSACEAE
ATE354631T1 (en) NUANCEMENT AGENTS
DK2266500T3 (en) Three-dimensional tissue structure
DK1378554T3 (en) Hydrophilic polymer concentrates
EP1597276A4 (en) THERAPEUTIC MOLECULES
DE602004018414D1 (en) Ophthalmic device
EP1638549A4 (en) NEW ANTIBACTERIAL AGENTS
DE602004017075D1 (en) Optometric instrument
DE602004001140D1 (en) Ophthalmic device
DE602004014547D1 (en) fundus camera
NO20062387L (en) Novel imaging agents
DK1597171T3 (en) THERAPEUTIC MICROSUM
SE0300137L (en) Infusion kit
DE602004015552D1 (en) Body Fat Monitor
DE602004018561D1 (en) Optometric instrument
DE602004000571D1 (en) Optometric instrument
DE602004008976D1 (en) Optometric instrument
ATA19412003A (en) SUPPORTING BODY MAT
EP1591451A4 (en) PEPTIDE CONJUGATE
FR2842104B1 (en) GENES INVOLVED IN EARLY CANITIS
EP1697515A4 (en) CONJUGATE DNA-EXCIPIENT
ITBO20030237A1 (en) LOCALIZED WHIRLPOOL DEVICE.
EP1597265A4 (en) GLYCOSOLIC ENCEPHALINE AGENTS
SE0403119D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050818

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20060215BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060515

17Q First examination report despatched

Effective date: 20070627

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080108